Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Facet Biotech, a developer of oncology drugs, has appointed Kurt von Emster to its board of directors.
Subscribe to our email newsletter
Since November 2000, he has been managing director of MPM BioEquities and serves as portfolio manager for the MPM BioEquities Fund. From July 1989 to November 2000, he was with the Franklin Templeton Group, most recently as a vice president and portfolio manager. Mr von Emster is currently a member of the board of directors at Somaxon Pharmaceuticals, a public biotechnology company.
Brad Goodwin, chairperson of Facet Biotech’s board of directors, said: “We are pleased to welcome Kurt, a biotechnology veteran, to Facet’s board. Kurt’s thorough understanding of the industry and his solid financial and investment expertise will provide a unique perspective as we work to establish Facet as a promising, oncology-focused biotechnology company.”